Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:PETS's Cash-to-Debt is ranked higher than
99% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.55 vs. NAS:PETS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:PETS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: No Debt Max: No Debt
Current: No Debt
0
No Debt
Equity-to-Asset 0.88
NAS:PETS's Equity-to-Asset is ranked higher than
95% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.41 vs. NAS:PETS: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:PETS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.87 Max: 0.95
Current: 0.88
-0.13
0.95
Interest Coverage No Debt
NAS:PETS's Interest Coverage is ranked higher than
100% of the 326 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.97 vs. NAS:PETS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:PETS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 21.10
Beneish M-Score: -2.52
WACC vs ROIC
8.33%
116.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 19.02
NAS:PETS's Operating Margin % is ranked higher than
95% of the 375 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. NAS:PETS: 19.02 )
Ranked among companies with meaningful Operating Margin % only.
NAS:PETS' s Operating Margin % Range Over the Past 10 Years
Min: 10.92  Med: 14.03 Max: 19.04
Current: 19.02
10.92
19.04
Net Margin % 14.88
NAS:PETS's Net Margin % is ranked higher than
94% of the 375 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.97 vs. NAS:PETS: 14.88 )
Ranked among companies with meaningful Net Margin % only.
NAS:PETS' s Net Margin % Range Over the Past 10 Years
Min: 6.99  Med: 8.89 Max: 14.88
Current: 14.88
6.99
14.88
ROE % 36.47
NAS:PETS's ROE % is ranked higher than
93% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.14 vs. NAS:PETS: 36.47 )
Ranked among companies with meaningful ROE % only.
NAS:PETS' s ROE % Range Over the Past 10 Years
Min: 18.7  Med: 26.36 Max: 36.47
Current: 36.47
18.7
36.47
ROA % 30.59
NAS:PETS's ROA % is ranked higher than
98% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.77 vs. NAS:PETS: 30.59 )
Ranked among companies with meaningful ROA % only.
NAS:PETS' s ROA % Range Over the Past 10 Years
Min: 16.88  Med: 23.59 Max: 30.59
Current: 30.59
16.88
30.59
ROC (Joel Greenblatt) % 154.88
NAS:PETS's ROC (Joel Greenblatt) % is ranked higher than
98% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.33 vs. NAS:PETS: 154.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:PETS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 91.28  Med: 106.52 Max: 154.88
Current: 154.88
91.28
154.88
3-Year Revenue Growth Rate 5.60
NAS:PETS's 3-Year Revenue Growth Rate is ranked lower than
61% of the 343 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.70 vs. NAS:PETS: 5.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:PETS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.3  Med: 8.45 Max: 58
Current: 5.6
-0.3
58
3-Year EBITDA Growth Rate 21.30
NAS:PETS's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 312 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.50 vs. NAS:PETS: 21.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:PETS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.2 Max: 112.8
Current: 21.3
0
112.8
3-Year EPS without NRI Growth Rate 27.90
NAS:PETS's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 288 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.30 vs. NAS:PETS: 27.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:PETS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.5 Max: 104.1
Current: 27.9
0
104.1
GuruFocus has detected 1 Warning Sign with PetMed Express Inc NAS:PETS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:PETS's 30-Y Financials

Financials (Next Earnings Date: 2019-01-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

PETS Guru Trades in

Q1 2018

PETS Guru Trades in Q1 2018

Joel Greenblatt 158,145 sh (+250.68%)
Caxton Associates 5,066 sh (unchged)
Lee Ainslie Sold Out
Ken Fisher 141,981 sh (-1.07%)
Chuck Royce 194 sh (-10.19%)
Jim Simons 1,633,000 sh (-0.12%)
» More
Q2 2018

PETS Guru Trades in Q2 2018

Lee Ainslie 5,525 sh (New)
Steven Cohen 5,200 sh (New)
Paul Tudor Jones 17,868 sh (New)
Philippe Laffont 20,309 sh (New)
Chuck Royce 372 sh (+91.75%)
Jim Simons 1,652,200 sh (+1.18%)
Caxton Associates Sold Out
Ken Fisher 105,658 sh (-25.58%)
Joel Greenblatt 91,240 sh (-42.31%)
» More
Q3 2018

PETS Guru Trades in Q3 2018

Ken Fisher 122,873 sh (+16.29%)
Jim Simons 1,748,415 sh (+5.82%)
Joel Greenblatt 161,569 sh (+77.08%)
Steven Cohen 90,818 sh (+1646.50%)
Paul Tudor Jones 32,692 sh (+82.96%)
Chuck Royce Sold Out
Philippe Laffont Sold Out
Lee Ainslie Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PETS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 541940    SIC: 5912
Compare:TSE:3385, TSE:9267, SZSE:002788, OHEL:OKDBV, MIC:PRTK, TSE:2664, XSWX:ROSE, SZSE:002462, IST:SELEC, SHSE:600833, XTER:SAE, HKSE:01345, WAR:NEU, XKLS:7668, SZSE:002758, NYSE:GNC, TSE:3194, MIC:APTK, TSE:3417, MEX:FRAGUA B » details
Traded in other countries:PQM.Germany,
Headquarter Location:USA
PetMed Express Inc is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications and other health products for dogs, cats, and horses direct to the consumer.

PetMed Express Inc sells medications, supplements, and general supplies, including food, beds, crates, and other items for dogs and cats. The company is a pharmacy licensed to dispense prescription medications in the United States, but also provides nonprescription pet medications and health products. PetMed Express regularly researches new products. The company markets its products directly to the consumer through television, online, and direct mail/print advertising campaigns.

Top Ranked Articles about PetMed Express Inc

PetMed Express d/b/a 1-800-PetMeds to Announce Its Third Quarter Financial Results on January 22, 2019
Risk-Reward With PetMed Express A small-cap dividend growth trade for risk-averse investors
PetMed Express (NASDAQ:PETS) is an online pet retailer headquartered in South Florida. The company has a consistent history of growth and dividend payments, and after trading north of $60 a share, its stock is back to trading at levels last seen in early 2017. Last week, PetMed Express (doing business as 1-800-PetMeds) posted second-quarter results with revenue up 7% to $71.4 million, and net income up 22.7% to $10.8 million, or 52 cents per share. Read more...
PetMed Express D/B/A 1-800-PetMeds to Announce its Second Quarter Financial Results on October 22, 2018
PetMed Express d/b/a 1-800-PetMeds Welcomes Leslie C.G. Campbell to Its Board of Directors
PetMed Express d/b/a 1-800-PETMEDS to Announce Its First Quarter Financial Results on July 23, 2018
PetMed Express D/B/A 1-800-PetMeds to Announce Its Fiscal Year End Financial Results on May 7, 2018
Report: Exploring Fundamental Drivers Behind PetMed Express, DCP Midstream Partners, LP, Gladstone Land, Federated National Holding, Farmer Brothers, and K12 — New Horizons, Emerging Trends, and Upcoming Developments
Analysis: Positioning to Benefit within PetMed Express, Omnicell, SITO Mobile, INDIA FUND INC, Forum Energy Technologies, and Kirkland's — Research Highlights Growth, Revenue, and Consolidated Results

Ratios

vs
industry
vs
history
PE Ratio 11.32
PETS's PE Ratio is ranked lower than
73% of the 303 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.85 vs. PETS: 11.32 )
Ranked among companies with meaningful PE Ratio only.
PETS' s PE Ratio Range Over the Past 10 Years
Min: 10.77  Med: 16.55 Max: 37.21
Current: 11.32
10.77
37.21
Forward PE Ratio 10.40
PETS's Forward PE Ratio is ranked lower than
76% of the 74 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.83 vs. PETS: 10.40 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 11.32
PETS's PE Ratio without NRI is ranked lower than
72% of the 303 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.28 vs. PETS: 11.32 )
Ranked among companies with meaningful PE Ratio without NRI only.
PETS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.77  Med: 16.55 Max: 37.21
Current: 11.32
10.77
37.21
Price-to-Owner-Earnings 15.90
PETS's Price-to-Owner-Earnings is ranked lower than
52% of the 215 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.12 vs. PETS: 15.90 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PETS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.6  Med: 17.9 Max: 49.49
Current: 15.9
8.6
49.49
PB Ratio 3.73
PETS's PB Ratio is ranked lower than
94% of the 363 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.73 vs. PETS: 3.73 )
Ranked among companies with meaningful PB Ratio only.
PETS' s PB Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.29 Max: 10.03
Current: 3.73
2.33
10.03
PS Ratio 1.68
PETS's PS Ratio is ranked lower than
93% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. PETS: 1.68 )
Ranked among companies with meaningful PS Ratio only.
PETS' s PS Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.54 Max: 4.04
Current: 1.68
0.84
4.04
Price-to-Free-Cash-Flow 12.38
PETS's Price-to-Free-Cash-Flow is ranked higher than
50% of the 151 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.33 vs. PETS: 12.38 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PETS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.83  Med: 16.9 Max: 2097.27
Current: 12.38
7.83
2097.27
Price-to-Operating-Cash-Flow 12.13
PETS's Price-to-Operating-Cash-Flow is ranked lower than
81% of the 196 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.41 vs. PETS: 12.13 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PETS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.65  Med: 15.17 Max: 36.37
Current: 12.13
7.65
36.37
EV-to-EBIT 7.30
PETS's EV-to-EBIT is ranked lower than
60% of the 318 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.28 vs. PETS: 7.30 )
Ranked among companies with meaningful EV-to-EBIT only.
PETS' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.7  Med: 9 Max: 22.2
Current: 7.3
4.7
22.2
EV-to-EBITDA 7.02
PETS's EV-to-EBITDA is ranked lower than
72% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.83 vs. PETS: 7.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
PETS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.5  Med: 8.75 Max: 21.3
Current: 7.02
4.5
21.3
EV-to-Revenue 1.39
PETS's EV-to-Revenue is ranked lower than
92% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.58 vs. PETS: 1.39 )
Ranked among companies with meaningful EV-to-Revenue only.
PETS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 1.3 Max: 3.7
Current: 1.39
0.5
3.7
PEG Ratio 0.90
PETS's PEG Ratio is ranked lower than
73% of the 177 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.19 vs. PETS: 0.90 )
Ranked among companies with meaningful PEG Ratio only.
PETS' s PEG Ratio Range Over the Past 10 Years
Min: 0.36  Med: 1.18 Max: 72.64
Current: 0.9
0.36
72.64
Shiller PE Ratio 19.52
PETS's Shiller PE Ratio is ranked lower than
84% of the 99 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.51 vs. PETS: 19.52 )
Ranked among companies with meaningful Shiller PE Ratio only.
PETS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.11  Med: 18.74 Max: 48.84
Current: 19.52
13.11
48.84
Current Ratio 6.99
PETS's Current Ratio is ranked higher than
95% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.20 vs. PETS: 6.99 )
Ranked among companies with meaningful Current Ratio only.
PETS' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 6.81 Max: 17.46
Current: 6.99
0.29
17.46
Quick Ratio 5.31
PETS's Quick Ratio is ranked higher than
95% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.77 vs. PETS: 5.31 )
Ranked among companies with meaningful Quick Ratio only.
PETS' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 4.39 Max: 14.61
Current: 5.31
0.11
14.61
Days Inventory 48.33
PETS's Days Inventory is ranked lower than
54% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.43 vs. PETS: 48.33 )
Ranked among companies with meaningful Days Inventory only.
PETS' s Days Inventory Range Over the Past 10 Years
Min: 45.18  Med: 63.9 Max: 78.88
Current: 48.33
45.18
78.88
Days Sales Outstanding 2.28
PETS's Days Sales Outstanding is ranked higher than
90% of the 278 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.58 vs. PETS: 2.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
PETS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.28  Med: 2.91 Max: 4.79
Current: 2.28
2.28
4.79
Days Payable 28.30
PETS's Days Payable is ranked lower than
78% of the 264 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 45.06 vs. PETS: 28.30 )
Ranked among companies with meaningful Days Payable only.
PETS' s Days Payable Range Over the Past 10 Years
Min: 11.53  Med: 14.4 Max: 32.71
Current: 28.3
11.53
32.71

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.44
PETS's Dividend Yield % is ranked higher than
50% of the 497 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.93 vs. PETS: 4.44 )
Ranked among companies with meaningful Dividend Yield % only.
PETS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.51  Med: 3.93 Max: 5.85
Current: 4.44
0.51
5.85
Dividend Payout Ratio 0.47
PETS's Dividend Payout Ratio is ranked lower than
65% of the 294 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.32 vs. PETS: 0.47 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PETS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.66 Max: 0.78
Current: 0.47
0.26
0.78
3-Year Dividend Growth Rate 7.70
PETS's 3-Year Dividend Growth Rate is ranked lower than
62% of the 190 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.70 vs. PETS: 7.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PETS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 26
Current: 7.7
0
26
Forward Dividend Yield % 4.61
PETS's Forward Dividend Yield % is ranked lower than
51% of the 470 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.22 vs. PETS: 4.61 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.11
PETS's 5-Year Yield-on-Cost % is ranked lower than
55% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.97 vs. PETS: 6.11 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PETS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.7  Med: 5.41 Max: 8.05
Current: 6.11
0.7
8.05
3-Year Average Share Buyback Ratio -0.60
PETS's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 214 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.50 vs. PETS: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PETS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -0.5 Max: 4.5
Current: -0.6
-45.6
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.04
PETS's Price-to-Net-Cash is ranked lower than
62% of the 29 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.00 vs. PETS: 7.04 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PETS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.77  Med: 8.98 Max: 34.59
Current: 7.04
3.77
34.59
Price-to-Net-Current-Asset-Value 4.80
PETS's Price-to-Net-Current-Asset-Value is ranked lower than
78% of the 118 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.13 vs. PETS: 4.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PETS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.56  Med: 6.1 Max: 40
Current: 4.8
2.56
40
Price-to-Tangible-Book 3.76
PETS's Price-to-Tangible-Book is ranked lower than
89% of the 328 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.14 vs. PETS: 3.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PETS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.37  Med: 5.26 Max: 243.33
Current: 3.76
2.37
243.33
Price-to-Intrinsic-Value-Projected-FCF 1.29
PETS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
77% of the 212 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.56 vs. PETS: 1.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PETS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 1.43 Max: 6.04
Current: 1.29
0.54
6.04
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.06
PETS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
99.99% of the 58 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.39 vs. PETS: 1.06 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
PETS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.49  Med: 0.64 Max: 2.16
Current: 1.06
0.49
2.16
Price-to-Median-PS-Value 1.09
PETS's Price-to-Median-PS-Value is ranked lower than
93% of the 312 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. PETS: 1.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PETS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.03 Max: 2.24
Current: 1.09
0.28
2.24
Price-to-Peter-Lynch-Fair-Value 0.75
PETS's Price-to-Peter-Lynch-Fair-Value is ranked lower than
78% of the 110 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.73 vs. PETS: 0.75 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PETS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.55  Med: 0.83 Max: 4.1
Current: 0.75
0.55
4.1
Price-to-Graham-Number 1.37
PETS's Price-to-Graham-Number is ranked lower than
88% of the 250 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.36 vs. PETS: 1.37 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PETS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 1.99 Max: 5.88
Current: 1.37
1.09
5.88
Earnings Yield (Greenblatt) % 13.70
PETS's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.71 vs. PETS: 13.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PETS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.5  Med: 11.1 Max: 21.2
Current: 13.7
4.5
21.2
Forward Rate of Return (Yacktman) % 19.80
PETS's Forward Rate of Return (Yacktman) % is ranked higher than
63% of the 255 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.05 vs. PETS: 19.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PETS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.2  Med: 12.8 Max: 25.9
Current: 19.8
1.2
25.9

More Statistics

Revenue (TTM) (Mil) $286.22
EPS (TTM) $ 2.07
Beta0.93
Volatility40.93%
52-Week Range $21.61 - 57.80
Shares Outstanding (Mil)20.67

Analyst Estimate

Mar19 Mar20 Mar21
Revenue (Mil $) 295 307 320
EBIT (Mil $) 55 58 62
EBITDA (Mil $) 57 60 64
EPS ($) 2.17 2.26 2.38
EPS without NRI ($) 2.17 2.26 2.38
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 1.00 1.10 1.21

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}